These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33388949)

  • 1. Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review.
    Savani M; Woerner K; Bu L; Birkenbach M; Skubitz KM
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):289-294. PubMed ID: 33388949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated-liposomal Doxorubicin-induced Glomerular Thrombotic Microangiopathy.
    Yokoyama S; Kakeshita K; Imamura T; Shima T; Fujioka H; Yamazaki H; Koike T; Kinugawa K
    Intern Med; 2024 Oct; 63(20):2839-2845. PubMed ID: 38462521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
    Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
    Skubitz KM; Blaes AH; Konety SH; Francis GS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.
    Grenader T; Goldberg A; Hadas-Halperin I; Gabizon A
    Anticancer Drugs; 2009 Jan; 20(1):15-20. PubMed ID: 19342997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
    Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD).
    Sánchez Henarejos P; Ros Martínez S; Marín Zafra GR; Alonso Romero JL; Navarrete Montoya A
    Clin Transl Oncol; 2009 Jul; 11(7):486-7. PubMed ID: 19574209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicity.
    Pease DF; Peterson BA; Gilles S; Hordinsky MK; Bohjanen KA; Skubitz KM
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):217-221. PubMed ID: 31041511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.
    Yao J; Pan S; Fan X; Jiang X; Yang Y; Jin J; Liu Y
    J Chemother; 2020 Jul; 32(4):202-207. PubMed ID: 32281493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term administration of pegylated liposomal doxorubicin at almost twice the recommended lifetime dose in 10 years without cardiotoxicity in a Japanese patient with HIV-associated Kaposi sarcoma.
    Yokota K; Yotsumoto M; Muramatsu T; Saito M; Kamikubo Y; Ichiki A; Chikasawa Y; Bingo M; Hagiwara T; Amano K; Fukutake K
    J Infect Chemother; 2020 Feb; 26(2):289-291. PubMed ID: 31537471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD).
    Kushnir CL; Angarita AM; Havrilesky LJ; Thompson S; Spahlinger D; Sinno AK; Tanner EJ; Secord AA; Roche KL; Stone RL; Fader AN
    Gynecol Oncol; 2015 Jun; 137(3):503-7. PubMed ID: 25735254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
    Lu YC; Ou-Yang FU; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
    In Vivo; 2016; 30(2):159-63. PubMed ID: 26912829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin.
    Blank N; Laskov I; Kessous R; Kogan L; Lau S; Sebag IA; Gotlieb WH; Rudski L
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):737-743. PubMed ID: 28801766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment.
    Carron PL; Padilla M; Maurizi Balzan J
    Hemodial Int; 2014 Oct; 18(4):846-7. PubMed ID: 25040096
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
    Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E
    Oncology; 2006; 70(2):141-6. PubMed ID: 16645327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal toxicity with liposomal doxorubicin in metastatic breast cancer.
    Yemm KE; Alwan LM; Malik AB; Salazar LG
    J Oncol Pharm Pract; 2019 Oct; 25(7):1738-1742. PubMed ID: 30170515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of formulation parameters and circulation time on PEGylated liposomal doxorubicin related hand-foot syndrome.
    Lian J; Tang X; Gui Y; Lu S; Song Y; Deng Y
    Int J Pharm; 2024 Nov; 665():124659. PubMed ID: 39260752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
    Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
    Yamada Y; Kawaguchi R; Ito F; Iwai K; Niiro E; Shigetomi H; Tanase Y; Kobayashi H
    J Obstet Gynaecol Res; 2017 Jul; 43(7):1194-1199. PubMed ID: 28544386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.